Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 5/20 | 0.61 |
| ▸ | KDM4E | B2RXH2 | 8/20 | 0.55 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.55 |
| ▸ | RAB9A | P51151 | 6/20 | 0.52 |
| ▸ | GAA | P10253 | 1/20 | 0.52 |
| ▸ | NPC1 | O15118 | 3/20 | 0.50 |
| ▸ | POLB | P06746 | 1/20 | 0.50 |
| ▸ | PTGDR2 | Q9Y5Y4 | 2/20 | 0.49 |
| ▸ | HPGD | P15428 | 4/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.49 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.49 |
| ▸ | TP53 | P04637 | 1/20 | 0.49 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.49 |
| ▸ | AHR | P35869 | 1/20 | 0.49 |
| ▸ | HTR2C | P28335 | 1/20 | 0.47 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL289862 | 0.88 | APP (0.55) | SMN1; SMN2KDM4EKMT2ARAB9AGAA | |
| SCHEMBL10995149 | 0.87 | CYP1A2 (0.51) | SMN1; SMN2KDM4EKMT2ARAB9ANPC1 | |
| SCHEMBL10997300 | 0.84 | LMNA (0.60) | SMN1; SMN2KDM4EKMT2ARAB9AGAA | |
| SCHEMBL3435514 | 0.84 | SMN1; SMN2 (0.49) | SMN1; SMN2KDM4EKMT2ARAB9AGAA | |
| SCHEMBL3435042 | 0.83 | KDM4E (0.57) | SMN1; SMN2KDM4EKMT2ARAB9AGAA | |
| SCHEMBL3435518 | 0.83 | SMN1; SMN2 (0.51) | SMN1; SMN2KDM4EKMT2ARAB9AGAA | |
| SCHEMBL10049076 | 0.82 | PTGDR2 (0.53) | SMN1; SMN2KDM4EKMT2ARAB9ANPC1 | |
| SCHEMBL3435617 | 0.82 | SMN1; SMN2 (0.69) | SMN1; SMN2KDM4EKMT2ARAB9AGAA | |
| SCHEMBL3436284 | 0.81 | KDM4E (0.59) | SMN1; SMN2KDM4EKMT2ARAB9AGAA | |
| SCHEMBL3371496 | 0.81 | SMN1; SMN2 (0.67) | SMN1; SMN2KDM4EKMT2ARAB9AGAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2594555-B1 | HETEROCYCLIC COMPOUND, AND p27 KIP1 DEGRADATION INHIBITOR | ASKA PHARM CO LTD (JP) | 2018-03-07 | — | — | EP | disclosed |
| US-9200008-B2 | Heterocyclic compound and p27Kip1 degradation inhibitor | ASKA PHARMACEUTICAL CO., LTD. (JP) | 2015-12-01 | — | — | US | disclosed |
| US-9200008-B2 | Heterocyclic compound and p27Kip1 degradation inhibitor | ASKA PHARMACEUTICAL CO., LTD. (JP) | 2015-12-01 | — | — | US | disclosed |
| EP-2594555-A1 | HETEROCYCLIC COMPOUND, AND p27 KIP1 DEGRADATION INHIBITOR | ASKA Pharmaceutical Co., Ltd. (JP) | 2013-05-22 | — | — | EP | disclosed |
| US-20130079306-A1 | HETEROCYCLIC COMPOUND AND p27Kip1 DEGRADATION INHIBITOR | ASKA PHARMACEUTICAL CO., LTD. (JP) | 2013-03-28 | — | — | US | disclosed |
| US-20130079306-A1 | HETEROCYCLIC COMPOUND AND p27Kip1 DEGRADATION INHIBITOR | ASKA PHARMACEUTICAL CO., LTD. (JP) | 2013-03-28 | — | — | US | disclosed |
| WO-2012002527-A1 | HETEROCYCLIC COMPOUND, AND p27 KIP1 DEGRADATION INHIBITOR | あすか製薬株式会社 (JP) | 2012-01-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130079306-A1 | HETEROCYCLIC COMPOUND AND p27Kip1 DEGRADATION INHIBITOR | CDKN1A, SKP2, CCNI | SMN1; SMN2 2696/4885KDM4E 1069/4885KMT2A 1012/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.